QRxPharma Ltd.  

(Public, ASX:QRX)   Watch this stock  
Find more results for QRX
+0.0010 (4.35%)
Jan 23 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.02 - 0.03
52 week 0.01 - 0.93
Open 0.02
Vol / Avg. 444,269.00/133,242.00
Mkt cap 3.77M
P/E     -
Div/yield     -
EPS -0.08
Shares 164.19M
Beta     -
Inst. own     -
Feb 23, 2015
Interim 2015 QRxPharma Ltd Earnings Release (Estimated) Add to calendar
Nov 19, 2014
QRxPharma Ltd Annual General Meeting
Oct 29, 2014
QRxPharma Ltd Annual Shareholders Meeting

Key stats and ratios

Q2 (Jun '14) 2014
Net profit margin -16418.00% -1991.19%
Operating margin -15664.00% -1990.30%
EBITD margin - -1979.85%
Return on average assets -113.82% -113.38%
Return on average equity -128.57% -140.18%
CDP Score - -


Level 1, 194 Miller Street
+61-2-94928021 (Phone)
+61-2-89200314 (Fax)

Website links


QRxPharma Limited is a commercial-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management. The Company�s complementary pain management product formulations- in both early and late stage clinical development, which include: MOXDUO IR, an immediate release oral capsule for acute pain; MOXDUO CR, a controlled release oral tablet chronic pain; and MOXDUO IV, an intravenous formulation for moderate to severe hospital-based pain. The Company is developing Dual Opioid formulation for treating patients with moderate to server acute or chronic pain. The Company�s Dual Opioid portfolio includes three complementary products: Q8003, an immediate-release oral capsule for acute pain; Q8011, a controlled-release oral tablet (with abuse deterrent and tamper resistant features) for chronic pain; Q8012, an intravenous formulation for moderate to severe pain secondary to hospital based procedures.

Officers and directors

Edward M. Rudnic Ph.D. Chief Executive Officer
Chris J Campbell Chief Financial Officer, Company Secretary
Age: 48
M. Janette Dixon Vice President - Global Business Development